{"id":2440,"date":"2025-11-06T18:20:42","date_gmt":"2025-11-06T18:20:42","guid":{"rendered":"https:\/\/www.worldpumpnews.com\/?p=2440"},"modified":"2025-11-06T18:20:42","modified_gmt":"2025-11-06T18:20:42","slug":"trump-says-prices-for-ozempic-other-weight-loss-drugs-to-drop-in-u-s-national","status":"publish","type":"post","link":"https:\/\/www.worldpumpnews.com\/?p=2440","title":{"rendered":"Trump says prices for Ozempic, other weight-loss drugs to drop in U.S. – National"},"content":{"rendered":"

<\/p>\n

\n

U.S. President Donald Trump, Eli Lilly and Novo Nordisk unveiled a deal on Thursday to slash the prices of popular GLP-1 weight\u2011loss drugs like Ozempic for the government\u2019s Medicare and Medicaid programs, as well as for cash payers.<\/p>\n

\"\"<\/p>\n

The move is aimed at increasing access to the treatments through U.S. Medicare for people aged 65 and over and the Medicaid program for low-income people, which together provide healthcare coverage for nearly half of all Americans.<\/p>\n

U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and\u00a0Trump\u00a0has been pressuring drugmakers to lower their prices to what patients pay elsewhere.<\/p>\n

\u201cGLP-1s have been top of mind and not just because of the cardiometabolic benefits that they provide, but also because it is an issue of fairness and utilization and pricing and access and affordability for the American people,\u201d an administration official told reporters.<\/p>\n

\n

Story continues below advertisement<\/p>\n<\/p><\/div>\n

Trump said the move \u201cwill save lives, improve the health of millions and millions of Americans,\u201d during an Oval Office announcement in which he referred to GLP-1s as a \u201cfat drug.\u201d<\/p>\n

\n
\n
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"Click
\n\t\t\t\t\t\t\t\t\t\t\t\t<\/p>\n

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\t\t\t\t\t\t<\/span>
\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n

Starter doses of rival weight\u2011loss pills being developed by Lilly and Novo, if approved, will cost $149 per month for all Medicare and Medicaid enrollees and via the White House\u2019s new direct-to-consumer site,\u00a0TrumpRx, senior administration officials said.<\/p>\n

\n

Story continues below advertisement<\/p>\n<\/p><\/div>\n

For currently available injectable GLP-1s used for diabetes and other covered health issues like Ozempic, Wegovy, Mounjaro and Zepbound, prices would fall to $245 per month for patients with Medicare or Medicaid, they said.<\/p>\n

On\u00a0TrumpRx, the average price of injectables and pills will start at or below $350 monthly and is expected to trend downward to $245 within two years.<\/p>\n

\n
\n\t\t\t\t\t\"Receive\n\t\t\t\t<\/div>\n
\n

Get weekly health news<\/h2>\n

Receive the latest medical news and health information delivered to you every Sunday.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n

In Medicare, patients\u2019 co-pays will be capped at $50 a month, officials said.<\/p>\n

Commercial health insurers would also be able to access prices estimated to be 25% lower than current cash prices, they said.<\/p>\n

The government will also expand coverage for GLP-1s under the deal, officials said, to overweight patients with prediabetes or heart problems, obese patients with comorbidities and severely obese patients, accounting for 10% of Medicare patients.<\/p>\n

The agreed prices will come into effect no later than January for cash payers, by mid-2026 for Medicare patients and on an ongoing basis for Medicaid enrollees depending on when states sign up.<\/p>\n

\n
\n
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"Click
\n\t\t\t\t\t\t\t\t\t\t\t\t<\/p>\n

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\t\t\t\t\t\t<\/span>
\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n

News of the pending announcement had pushed shares of the two companies higher as investors bet on increased patient access in government health programs. Denmark\u2019s Novo rose more than 1%, while Eli Lilly shares were flat in early trading.<\/p>\n

\n

Story continues below advertisement<\/p>\n<\/p><\/div>\n

Administration officials said the companies would get relief from\u00a0tariffs\u00a0as part of the deal. They also said Novo and Lilly will receive fast-track regulatory vouchers for some of their drugs.<\/p>\n

Novo\u2019s Wegovy and Eli Lilly\u2019s Zepbound are the only highly effective GLP-1 weight-loss drugs sold mainly in the U.S. as weekly injections. List prices top $1,000 a month, though both offer cash buyers a $499 monthly supply.<\/p>\n

The monthly price in the U.S. is far above what other countries pay. In Canada, patients pay an average of $150 per month ($210 CAD), while some European nations\u2019 price is under $100 monthly.<\/p>\n

Currently, Medicare does not readily cover the drugs for obesity. Coverage in Medicaid, which is run by each state and jointly financed with the federal government, varies.<\/p>\n

\n

\n\t\t\t\t<\/p>\n

\n\t\t\t\tDrugmaker growth potential\t\t\t<\/h2>\n<\/p><\/div>\n